DERM - Dermira Inc Stock Price, Fair Value and News

3.45USD-0.17 (-4.70%)Market Closed

Market Summary

USD3.45-0.17

Market Closed

-4.70%

DERM Stock Price

View Fullscreen

DERM RSI Chart

DERM Valuation

Market Cap

68.2M

Price/Earnings (Trailing)

-16.39

Price/Sales (Trailing)

0.85

EV/EBITDA

-25.1

Price/Free Cashflow

57.91

DERM Price/Sales (Trailing)

DERM Profitability

Operating Margin

66.22%

EBT Margin

-4.92%

Return on Equity

-32.11%

Return on Assets

-6.25%

Free Cashflow Yield

1.73%

DERM Fundamentals

DERM Revenue

Revenue (TTM)

80.0M

Rev. Growth (Yr)

6.69%

Rev. Growth (Qtr)

-14.6%

DERM Earnings

Earnings (TTM)

-4.2M

Earnings Growth (Yr)

-3.02%

Earnings Growth (Qtr)

-387.26%

Breaking Down DERM Revenue

Last 7 days

-1.7%

Last 30 days

-10.6%

Last 90 days

-19.0%

Trailing 12 Months

233.3%

How does DERM drawdown profile look like?

DERM Financial Health

Current Ratio

1.21

Debt/Equity

1.13

Debt/Cashflow

0.08

DERM Investor Care

Shares Dilution (1Y)

10.95%

Diluted EPS (TTM)

-0.24

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	80.0M	0	0	0
2023	62.6M	61.5M	79.9M	79.2M
2022	75.7M	78.7M	75.2M	73.7M
2021	49.2M	53.8M	58.5M	63.1M
2020	0	0	0	44.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Dermira Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 25, 2024	rosenwald lindsay a md	bought	30,400	3.04	10,000	-
Mar 22, 2024	smith justin adam	bought	104,100	3.47	30,000	-
Mar 22, 2024	maraoui claude	bought	34,790	3.479	10,000	president & ceo
Mar 22, 2024	rosenwald lindsay a md	bought	68,000	3.4	20,000	-
Feb 22, 2024	benesch joseph	sold	-9,187	3.75	-2,450	interim cfo
Nov 28, 2023	paley jeffrey	sold	-9,108	5.22	-1,745	-
Nov 08, 2023	paley jeffrey	sold	-958	3.76	-255	-
Nov 07, 2023	paley jeffrey	sold	-7,812	3.48	-2,245	-
Oct 13, 2023	smith justin adam	bought	98,340	2.98	33,000	-
Oct 06, 2023	paley jeffrey	bought	44,700	2.98	15,000	-

Which funds bought or sold DERM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-159,834	-	-%
May 15, 2024	Royal Bank of Canada	reduced	-79.31	-	-	-%
May 15, 2024	CITADEL ADVISORS LLC	sold off	-100	-65,416	-	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	new	-	73,471	73,471	-%
May 15, 2024	TANG CAPITAL MANAGEMENT LLC	new	-	510,140	510,140	0.05%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-51.86	-299,268	132,911	-%
May 15, 2024	PRELUDE CAPITAL MANAGEMENT, LLC	new	-	55,421	55,421	-%
May 15, 2024	Tower Research Capital LLC (TRC)	new	-	18,540	18,540	-%
May 15, 2024	Cubist Systematic Strategies, LLC	sold off	-100	-135,003	-	-%
May 15, 2024	Man Group plc	sold off	-100	-105,224	-	-%

Are Funds Buying or Selling DERM?

Are funds buying DERM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own DERM

No. of Funds

Unveiling Dermira Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Dec 29, 2022	b. riley financial, inc.	4.9%	864,695	SC 13G/A
Aug 17, 2022	fortress biotech, inc.	56.9%	10,010,467	SC 13G
Feb 11, 2022	b. riley financial, inc.	5.2%	864,695	SC 13G

Recent SEC filings of Dermira Inc

View All Filings

Date Filed	Form Type	Document
May 14, 2024	10-Q	Quarterly Report
May 13, 2024	8-K	Current Report
May 01, 2024	8-K	Current Report
Apr 29, 2024	DEFA14A	DEFA14A
Apr 29, 2024	DEF 14A	DEF 14A
Mar 29, 2024	10-K	Annual Report
Mar 27, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading

Peers (Alternatives to Dermira Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	372.2B	85.6B	6.82%	-1.69%	9.67	4.35	5.68%	202.39%
MRK	332.3B	61.4B	4.65%	15.09%	144.1	5.41	6.11%	-82.30%
AMGN	167.7B	29.5B	18.35%	39.38%	44.55	5.68	12.76%	-52.47%
PFE	162.3B	57.8B	12.71%	-21.46%	129.52	2.81	76.51%	-86.81%
GILD	84.4B	27.4B	1.23%	-13.37%	174.21	3.07	1.51%	-91.32%
TEVA	18.4B	16.0B	23.52%	97.09%	-37.29	1.15	7.23%	71.10%
MID-CAP
ALKS	4.1B	1.7B	0.67%	-19.91%	9.41	2.37	54.01%	364.56%
PRGO	4.1B	4.6B	-0.70%	-10.77%	-528.11	0.89	-0.06%	94.55%
BHC	2.5B	9.0B	-21.94%	-21.03%	-5.45	0.28	10.01%	-27.45%
AMPH	2.1B	676.2M	8.56%	-0.82%	13.75	3.14	30.38%	66.04%
SMALL-CAP
TLRY	1.5B	743.2M	15.12%	-18.85%	-4.35	2.06	24.65%	80.36%
TXMD	25.8M	1.3M	18.52%	-47.17%	-3.49	19.84	-98.14%	-104.71%
ACRX	18.4M	89.6M	6.93%	25.60%	-1.29	0.19	287.27%	-129.41%
AGRX	2.5M	21.5M	2.70%	-90.89%	-0.32	0.12	66.16%	61.83%
ACOR	633.5K	115.7M	-50.00%	-97.38%	0	0.01	-2.22%	-352.48%

Dermira Inc News

Latest updates

Dermira Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)															(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Revenue	-14.6%	13,030,000	15,257,000	34,539,000	17,172,000	12,213,000	15,966,000	16,116,000	18,291,000	23,296,000	17,517,000	19,610,000	15,288,000	10,719,000	10,083,000	9,447,000
Cost Of Revenue	13.3%	6,816,000	6,015,000	6,429,000	7,767,000	6,449,000	7,718,000	7,221,000	7,633,000	8,203,000	9,525,000	11,167,000	7,484,000	3,908,000	-	3,379,000
Costs and Expenses	33.2%	23,120,000	17,361,000	17,294,000	24,825,000	21,774,000	25,961,000	25,608,000	25,433,000	24,184,000	26,574,000	32,256,000	29,051,000	10,134,000	-	9,208,000
S&GA Expenses	-14.4%	8,420,000	9,841,000	8,636,000	12,141,000	13,292,000	13,987,000	15,575,000	15,191,000	14,715,000	15,057,000	10,755,000	7,795,000	6,226,000	-	5,829,000
R&D Expenses	423.9%	7,884,000	1,505,000	2,229,000	1,774,000	2,033,000	4,256,000	2,812,000	2,609,000	1,266,000	-	718,000	29,000	-	-	-
EBITDA Margin	-19.9%	-0.03	-0.02	-0.12	-0.60	-0.58	-0.37	-0.36	-0.38	-0.49	-0.56	0.13	0.15	0.16	0.18	-
Interest Expenses	2183.3%	548,000	24,000	268,000	756,000	650,000	617,000	559,000	454,000	389,000	4,098,000	1,373,000	1,342,000	221,000	-	-
Income Taxes	-100.0%	-	126,000	95,000	78,000	7,000	13,000	10,000	-64,000	104,000	8,335,000	-3,375,000	-3,422,000	96,000	-	23,000
Earnings Before Taxes	-417.7%	-10,442,000	-2,017,000	16,884,000	-8,363,000	-10,136,000	-10,629,000	-10,070,000	-7,592,000	-1,274,000	-13,416,000	-14,021,000	-15,287,000	364,000	-	52,000
EBT Margin	-7.3%	-0.05	-0.05	-0.15	-0.64	-0.61	-0.40	-0.43	-0.46	-0.58	-0.67	0.12	0.13	0.15	0.16	-
Net Income	-387.3%	-10,442,000	-2,143,000	16,789,000	-8,363,000	-10,136,000	-10,642,000	-10,080,000	-7,528,000	-1,378,000	-21,751,000	-10,646,000	-11,865,000	268,000	-	29,000
Net Income Margin	-6.8%	-0.05	-0.05	-0.15	-0.64	-0.61	-0.40	-0.54	-0.52	-0.60	-0.70	0.09	0.10	0.11	0.12	-
Free Cashflow	69.6%	-5,019,000	-16,520,000	18,747,000	3,969,000	-956,000	-3,836,000	-7,282,000	-3,300,000	884,000	-3,206,000	7,102,000	-7,438,000	1,361,000	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4
Assets	-13.4%	67.00	77.00	66.00	70.00	96.00	105	108	113	121	97.00	89.00	52.00
Current Assets	-16.7%	47.00	56.00	45.00	48.00	61.00	78.00	80.00	84.00	90.00	84.00	67.00	35.00
Cash Equivalents	-12.2%	24.00	27.00	25.00	8.00	17.00	32.00	35.00	38.00	41.00	49.00	22.00	8.00
Inventory	3.7%	11.00	10.00	11.00	12.00	13.00	14.00	15.00	16.00	16.00	10.00	12.00	1.00
Liabilities	-5.1%	54.00	56.00	49.00	70.00	88.00	88.00	82.00	79.00	79.00	55.00	101	42.00
Current Liabilities	-7.0%	39.00	42.00	49.00	68.00	77.00	67.00	61.00	60.00	61.00	52.00	60.00	28.00
Long Term Debt	0.4%	15.00	15.00	-	-	10.00	20.00	20.00	15.00	15.00	-	-	-
LT Debt, Current	-	-	-	-	10.00	10.00	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	15.00	-	-	10.00	20.00	20.00	15.00	15.00	-	-	-
Shareholder's Equity	-36.4%	13.00	20.00	17.00	0.00	7.00	17.00	26.00	35.00	41.00	42.00	-	10.00
Retained Earnings	-14.4%	-82.80	-72.35	-70.21	-87.00	-78.64	-68.50	-57.86	-47.78	-40.25	-38.87	-17.12	5.00
Additional Paid-In Capital	3.3%	96.00	93.00	88.00	87.00	86.00	85.00	84.00	83.00	82.00	81.00	5.00	5.00
Shares Outstanding	8.4%	20.00	18.00	18.00	18.00	18.00	18.00	17.00	17.00	17.00	10.00	9.00	9.00
Float	-	-	-	-	12.00	-	-	-	26.00	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Cashflow From Operations	69.6%	-5,019	-16,520	18,747	3,969	-956	-3,836	-7,282	-3,300	884	-3,206	7,102	-7,438	1,361	-	-
Share Based Compensation	165.8%	1,406	529	558	873	646	1,440	1,438	774	773	2,425	8.00	11.00	22.00	-	-
Cashflow From Investing	-	-	-	-	-	-5,000	-	-	-	-20,000	-1,200	-	-	-	-	-
Cashflow From Financing	-91.5%	1,637	19,210	-10,978	-13,088	52.00	948	4,031	111	11,366	31,798	11,211	616	9,391	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

DERM Income Statement

2024-03-31

Unaudited Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Product revenue, net	$ 13,030	$ 12,165
Other revenue		48
Total revenue	13,030	12,213
Operating expenses
Cost of goods sold - product revenue	6,816	6,449
Research and development	7,884	2,033
Selling, general and administrative	8,420	13,292
Total operating expenses	23,120	21,774
Loss from operations	(10,090)	(9,561)
Other expense (income)
Interest income	(217)	(122)
Interest expense	548	650
Foreign exchange transaction losses	21	47
Total other expense (income)	352	575
Loss before income taxes	(10,442)	(10,136)
Net loss	$ (10,442)	$ (10,136)
Net loss per common share:
Basic	$ (0.53)	$ (0.57)
Diluted	$ (0.53)	$ (0.57)
Weighted average number of common shares:
Basic	19,757,449	17,807,194
Diluted	19,757,449	17,807,194

DERM Balance Sheet

2024-03-31

Unaudited Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 24,057	$ 27,439
Accounts receivable, net of reserves	9,799	15,222
Inventory	10,580	10,206
Prepaid expenses and other current assets	2,577	3,588
Total current assets	47,013	56,455
Intangible assets, net	19,473	20,287
Operating lease right-of-use asset, net	79	101
Other assets	6	6
Total assets	66,571	76,849
Current liabilities
Accounts payable	15,343	18,149
Due to related party	$ 198	$ 195
Other Liability, Current, Related Party, Type [Extensible Enumeration]	us-gaap:RelatedPartyMember	us-gaap:RelatedPartyMember
Accrued expenses	$ 20,033	$ 20,350
Accrued interest	241	22
Income taxes payable	37	53
Installment payments - licenses, short-term	3,000	3,000
Operating lease liability, short-term	84	99
Total current liabilities	38,936	41,868
Term loan, long-term, net of debt discount	14,684	14,622
Operating lease liability, long-term		9
Total liabilities	53,620	56,499
Commitments and contingencies (Note 13)
Stockholders' equity
Additional paid-in capital	95,746	92,703
Accumulated deficit	(82,797)	(72,355)
Total stockholders' equity	12,951	20,350
Total liabilities and stockholders' equity	66,571	76,849
Common stock
Stockholders' equity
Common stock	1	1
Common Stock Class A
Stockholders' equity
Common stock	$ 1	$ 1

About Dermira Inc

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Zilxi, a topical minocycline treatment for inflammatory lesions; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

CEO	Mr. Claude Maraoui
WEBSITE	https://journeymedicalcorp.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	20

Dermira Inc Frequently Asked Questions

What is the ticker symbol for Dermira Inc? What does DERM stand for in stocks?

DERM is the stock ticker symbol of Dermira Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Dermira Inc (DERM)?

As of Fri May 17 2024, market cap of Dermira Inc is 68.16 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DERM stock?

You can check DERM's fair value in chart for subscribers.

What is the fair value of DERM stock?

You can check DERM's fair value in chart for subscribers. The fair value of Dermira Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Dermira Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DERM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Dermira Inc a good stock to buy?

The fair value guage provides a quick view whether DERM is over valued or under valued. Whether Dermira Inc is cheap or expensive depends on the assumptions which impact Dermira Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DERM.

What is Dermira Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, DERM's PE ratio (Price to Earnings) is -16.39 and Price to Sales (PS) ratio is 0.85. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DERM PE ratio will change depending on the future growth rate expectations of investors.